Clinical trial
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary…
NCT00127881 · Emergent Product Development Seattle LLC, Industry · Terminated
Key facts
| NCT number | NCT00127881 |
|---|---|
| Title | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome |
| Official title | Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy |
| Lead sponsor | Emergent Product Development Seattle LLC, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mycosis Fungoides, Sezary Syndrome |
| Intervention type | Drug |
| Interventions | HuMax-CD4 (zanolimumab) |
| Enrollment | 76 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2014 |
| First posted | Aug 9, 2005 |
| Last update posted | Jul 26, 2012 |
| Countries | France, Germany, Italy, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: